Bain Capital-backed Emcure Pharma IPO to open on July 3: Namita Thapar to offload stake—Top 10 things to know | Stock Market News

Emcure Pharmaceuticals IPO: The mainboard initial public offering (IPO) of leading pharma major Emcure Pharmaceuticals Ltd will open for subscription on Wednesday, July 3, 2024. The company develops, manufactures, and markets a wide range of pharmaceutical products across several major therapeutic areas. Emcure Pharma’s product portfolio consists of injectables, biotherapeutics, and orals. The research and development (R&D)-driven firm has targeted markets in over 70 countries, with a significant presence in Europe, Canada, and India.

The selling shareholders in the public issue include promoters Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, Samit Satish Mehta, and investor BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital. Between March 31, 2024, and March 31, 2023, Emcure Pharma’s profit after tax (PAT) decreased 6.1 per cent while its sales rose 11.33 per cent.

According to the red herring prospectus (RHP), the company’s listed peers are Dr. Reddy’s Laboratories Ltd (with a P/E of 17.93), Cipla Ltd (with a P/E of 30.10), Alkem Laboratories Ltd (with a P/E of 33.86), Torrent Pharmaceutical Ltd (with a P/E of 57.74), Mankind Pharma (with a P/E of 45.30), Abbott India Ltd (with a P/E of 47.43), J. B. Chemicals & Pharmaceutical Ltd (with a P/E of 50.49).

Source link


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

India stock market has found its Midas...! | Stock Market News

Sun Jun 30 , 2024
The current domestic rally stands on solid ground, Sensex is poised to potentially breach the 80,000 marks. This surge began with the formation of a stable coalition government, instilling confidence among investors. Since June 4th, major indices have climbed 10%, significantly reducing the country’s risk profile by reversing net outflows […]

You May Like